FDA accepts BLA for fixed-dose combination of Perjeta + Herceptin with hyaluronidase, by subcutaneous injection in combination with I.V. chemotherapy for the treatment of HER2-positive breast cancer. Genentech/Roche
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest